Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Cinacalcet Open Label Study to Reach K/DOQI Levels|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00113958